



Venixxa™

INTRODUCING VENIXXA™: A **NEW** ORAL TREATMENT OPTION IN PATIENTS WITH MILD-TO-MODERATE CHRONIC VENOUS DISEASE AND HEMORRHOIDS¹

RECOMMENDED USE IN MILD-TO-MODERATE CHRONIC VENOUS DISEASE:1



- · Helps to reduce lower-leg edema associated with mild-to-moderate chronic venous disease
- · Helps to relieve signs and symptoms of mild-to-moderate chronic venous disease, such as varicose and spider veins, pain in the legs, sensation of heaviness, sensation of swelling, and functional discomfort

RECOMMENDED DOSE AND DURATION OF USE IN MILD-TO-MODERATE CHRONIC VENOUS DISEASE:1





1 tablet twice daily, midday and evening with meals

- Should be used for a minimum of 2 months to see beneficial effects
- If response is inadequate or unsatisfactory after 2 months, reconsider diagnosis, as edema may have alternative causes

QUANTITY PER BOX IN PATIENTS WITH MILD-TO-MODERATE CHRONIC VENOUS DISEASE:



30 tablets (500 mg each)



	Chronic venous disease	Hemorrhoids	
UPC	7 71547 00411 9	7 71547 00412 6	
NPN	80078651		

Known adverse reactions:

Hypersensitivity/allergy, gastrointestinal discomfort, dizziness, headaches, malaise, and skin reactions have been known to occur; in which case, patients should discontinue use and consult a healthcare practitioner.

Cautions and warnings:

Treatment should be avoided during pregnancy and breastfeeding. The patient should be advised to consult a healthcare practitioner:

• if symptoms of chronic venous disease persist or worsen, or in the event of inflammation of the skin, thrombophlebitis or subcutaneous induration, severe pain, ulcers, sudden swelling of one or both legs, cardiac or renal insufficiency or disorder;



RECOMMENDED USE IN HEMORRHOIDS:1

- Helps to reduce signs and symptoms associated with hemorrhoids, such as anal discharge, bleeding, discomfort, inflammation (proctitis), itching (pruritus), pain, redness (erythema), sensation of needing to pass stools (tenesmus), and swelling (edema)
- · Helps to reduce the duration, intensity, and recurrence of acute hemorrhoidal episodes

RECOMMENDED DOSE AND DURATION OF USE IN ACUTE **HEMORRHOIDS** (1-WEEK TREATMENT COURSE):1



RECOMMENDED DOSE AND DURATION OF USE IN HEMORRHOIDS:¹



 Patient should consult a healthcare practitioner for use beyond 2 months

OUANTITY PER BOX IN PATIENTS WITH HEMORRHOIDS:



Distributors		Chronic venous disease	Hemorrhoids
McKesson		119182	119183
Kohl &	& Frisch	158813	158814

- if symptoms of hemorrhoids persist or worsen, if acute hemorrhoidal episode persists after 7 days, or if hemorrhoids are accompanied by rectal bleeding or a change in bowel habits;
- · prior to taking prescription medication.

For more information:

See Warnings, Cautions, and Directions of Use at https://health-products.canada.ca/lnhpd-bdpsnh/index-eng.jsp for information to assist in benefit-risk assessment. Always direct the patient to read the label. The Terms of Market Authorization are also available upon request by calling 1-888-902-9700.

∍ference: Venixxa™ Product Licence. Servier Canada Inc., 2017.

© 2017 Servier Canada Inc. Venixxa™ is a trademark of Servier Canada Inc.

MEMBER OF INNOVATIVE MEDICINES CANADA





